Optiscan Imaging Limited

Equities

OIL

AU000000OIL4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 02:10:47 2024-04-30 am EDT 5-day change 1st Jan Change
0.089 AUD +4.71% Intraday chart for Optiscan Imaging Limited +8.54% +5.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate MT
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Optiscan Imaging Secures AU$3 Million Research Grant for Endomicroscope Device; Shares Rise 8% MT
Optiscan Imaging Appoints COO MT
Optiscan Imaging Limited Appoints Brendan Fafiani to the Role of Chief Operating Officer, Effective 6 November 2023 CI
Cancer Images from Optiscan's Platform Comparable With Conventional Histology Analysis, Study Says MT
Optiscan Imaging Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Optiscan Imaging Completes Key Milestone for Telepathology Project MT
Optiscan Imaging Establishes New Commercial Operation in the US MT
Optiscan Imaging Confirms High Diagnostic Rate of Imaging Device MT
Optiscan Imaging Receives US FDA Feedback for Oral Imaging Product MT
Optiscan Imaging Limited Intends to Pursue De Novo Pathway for InVivage CI
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Optiscan Imaging Limited Announces Partnership with Prolucid Technologies to Develop AI Algorithms CI
Optiscan Imaging Proposes Issuance of 6 Million Securities MT
Optiscan Imaging Acquiring Clinical Datasets from Managing Director; Shares Rise 4% MT
Optiscan Imaging Secures R&D Tax Rebate MT
Optiscan Imaging Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Optiscan Imaging Files US FDA Application for Oral Tissue Imaging Device MT
Optiscan Submits FDA 510(k) Application for InVivage Device CI
Optiscan Imaging Limited Announces Strategic Distribution Partnership -­ Additional Information CI
Optiscan Imaging Appoints China Distributor for Research, Preclinical Device MT
Optiscan Imaging Limited Announces Strategic Distribution Partner for China CI
Optiscan Imaging Limited Appointment of Sean Gardiner as Non-Executive Director CI
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Chart Optiscan Imaging Limited
More charts
Optiscan Imaging Limited is an Australia-based company, which is engaged in the development, manufacturing and commercialization of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The Company’s technology enables real-time, non-destructive, three-dimensional (3D), in-vivo imaging at the single-cell level. It provides real-time microscopic imaging tools to healthcare providers and researchers to enable the early detection and management of disease. Its InVivage device is developed for clinical use in oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a hand-held, confocal microscope designed for pre-clinical use. This device is targeted for use by universities and medical research institutions to explore potential applications of the technology through laboratory testing of tissue samples.
More about the company
  1. Stock Market
  2. Equities
  3. OIL Stock
  4. News Optiscan Imaging Limited
  5. Optiscan Imaging Receives US FDA Feedback for Oral Imaging Product